Wegovy is the better choice for weight loss, and it’s not particularly close. Both medications contain the exact same active ingredient, semaglutide, but Wegovy is FDA-approved specifically for weight management and delivers a higher maximum dose: 2.4 mg per week compared to Ozempic’s 2 mg. That dosage difference, combined with Wegovy’s dedicated approval for obesity, makes it the purpose-built option.
Same Drug, Different Purpose
Wegovy and Ozempic are both once-weekly injectable pens made by the same manufacturer, Novo Nordisk. They work identically in your body: semaglutide mimics a gut hormone that slows digestion, reduces appetite, and signals your brain that you’re full. The difference is regulatory and practical.
Ozempic is FDA-approved to treat type 2 diabetes. Weight loss happens as a side effect, and doctors sometimes prescribe it off-label for that purpose, but it was designed and studied primarily for blood sugar control. Wegovy, on the other hand, was approved specifically for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related health condition. It also carries an approval to reduce the risk of heart attack, stroke, and cardiovascular death in adults with established heart disease and excess weight, plus a newer indication for a type of fatty liver disease.
How Much Weight You Can Expect to Lose
The clinical trials tell a clear story. In the STEP trials, which tested Wegovy at its standard 2.4 mg maintenance dose, participants without diabetes lost an average of 17.5% of their body weight over about 72 weeks. For someone starting at 250 pounds, that translates to roughly 44 pounds. A higher investigational dose of 7.2 mg (not yet the standard prescription) pushed average weight loss to nearly 21%.
Ozempic’s weight loss numbers are more modest, reflecting both its lower dose ceiling and its study population of people with type 2 diabetes (who typically lose less weight on these medications). In the SUSTAIN FORTE trial, participants on the 2.0 mg dose lost an average of about 15 pounds over 40 weeks, compared to roughly 13 pounds on the 1.0 mg dose. These are meaningful results for a diabetes drug, but they fall well short of what Wegovy delivers at its higher dose over a longer treatment period.
The gap makes physiological sense. More semaglutide means stronger appetite suppression and greater metabolic effects. Wegovy’s 2.4 mg dose is 20% higher than Ozempic’s maximum 2.0 mg, and patients reach that dose through a structured titration designed specifically for weight loss goals.
The Dose Escalation Process
Both medications start at low doses and gradually increase to minimize side effects, but the schedules differ. Ozempic typically starts at 0.25 mg weekly for four weeks, then moves to 0.5 mg, and eventually up to the 1.0 mg or 2.0 mg maintenance dose. Wegovy follows a longer ramp-up because it’s aiming for a higher target: you’ll move through 0.25 mg, 0.5 mg, 1.0 mg, and 1.7 mg in four-week intervals before reaching the 2.4 mg maintenance dose. The full escalation takes about four to five months.
If you’re already on Ozempic at 2.0 mg and want to switch to Wegovy, the transition can be relatively straightforward. After at least four weeks on Ozempic 2.0 mg, you can move directly to Wegovy 2.4 mg without repeating the entire titration from scratch.
Side Effects Are Nearly Identical
Since both drugs are semaglutide, the side effect profile is essentially the same. The most common complaints are gastrointestinal: nausea affects roughly 1 in 5 people taking semaglutide, diarrhea occurs in about 1 in 10, and vomiting in about 9%. These symptoms are usually worst during dose increases and tend to fade as your body adjusts.
The one caveat is that Wegovy’s higher dose may trigger slightly more intense GI symptoms at the top end of the titration. This is why the gradual dose escalation matters. Skipping steps or increasing too quickly is the most common reason people struggle with side effects on either medication.
Cardiovascular Benefits
Wegovy has a significant advantage beyond the scale. The SELECT trial, a large cardiovascular outcomes study, found that semaglutide 2.4 mg reduced the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% compared to placebo in people with established heart disease and excess weight who did not have diabetes. This led to Wegovy’s FDA approval for cardiovascular risk reduction, an indication Ozempic does not carry.
Cost and Insurance Coverage
This is where the practical reality gets complicated. Wegovy’s list price runs around $1,300 per month, while Ozempic lists at roughly $900 per month. Neither is cheap, and insurance coverage is inconsistent at best.
Most private insurance companies and federal health programs don’t cover weight-loss drugs. Medicare has been explicitly prohibited by law from covering weight-loss medications since 2003, though bipartisan legislation has been introduced to change that. Because Ozempic is approved for diabetes, it’s far easier to get covered if you have a type 2 diabetes diagnosis. Wegovy’s weight management indication often falls into the gap where insurers classify it as elective or lifestyle-related.
Novo Nordisk has introduced some direct-to-consumer pricing to address the affordability problem. The company offered the two lowest doses of both Ozempic and Wegovy at $199 per month for two months, with higher doses priced at $349 per month after that initial period. A partnership with Costco also made low-dose versions available for $499 per month out of pocket. These programs change frequently, so the specific numbers may shift, but they signal that the manufacturer recognizes list prices are a barrier.
Which One Should You Actually Pursue?
If your primary goal is weight loss, Wegovy is the more effective option. It’s specifically designed for it, reaches a higher dose, and has the clinical trial data to back up greater average weight loss. It also offers the added cardiovascular benefit that Ozempic lacks in its labeling.
The reason many people end up on Ozempic for weight loss comes down to access. If you have type 2 diabetes, Ozempic may be covered by your insurance while Wegovy is not. Some doctors prescribe Ozempic off-label for weight loss when Wegovy is unavailable or unaffordable. In those situations, Ozempic still produces meaningful weight loss, just not as much as Wegovy at its full dose.
For people who can access either medication without cost being the deciding factor, the evidence points clearly toward Wegovy. It was built for weight loss, tested for weight loss, and approved for weight loss. Ozempic is an effective diabetes treatment that happens to help people lose weight along the way.